Teva's healthy Q3 adrift in sea of uncertainty
This article was originally published in Scrip
Teva Pharmaceutical Industries reported revenue growth and a return to net profit in the third quarter. However, news of relatively healthy third-quarter results will be cold comfort to the firm's investors, following the sudden departure of CEO Jeremy Levin on 31 October, apparently against his will, and with the outlook continuing to look decidedly shaky for the company once its primary profit engine, the branded multiple sclerosis drug Copaxone (glatiramer acetate injection), faces generic competition in the US potentially from May 2014.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.